Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation in high-grade B-cell non-Hodgkin lymphoma in patients >60 years
2008-003828-38Phase 2Terminated
- Sponsor
- San Salvatore Hospital of L'Aquila
- Start
- Jul 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), sponsored by San Salvatore Hospital of L'Aquila. Primary endpoints: 3-year event-free survival and Cumulative response rate. Started Jul 2008; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2008-003828-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003828-38.